The Role of Cystic Fibrosis Transmembrane Conductance Regulator Modulators After Liver Transplantation in Persons With Cystic Fibrosis.
| Autor: | Maradiaga RD; Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH., Ramsey ML; Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH., Kirkby SE; Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH., Sobotka LA; Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ACG case reports journal [ACG Case Rep J] 2024 Jan 16; Vol. 11 (1), pp. e01261. Date of Electronic Publication: 2024 Jan 16 (Print Publication: 2024). |
| DOI: | 10.14309/crj.0000000000001261 |
| Abstrakt: | Despite advances in treatment for cystic fibrosis (CF), liver disease remains a major contributor to morbidity and mortality for persons with CF. Therefore, liver transplantation may be considered in end-stage CF-related liver disease. We present a young patient with CF who underwent solo liver transplantation and has successfully restarted on elexacaftor/tezacaftor/ivacaftor without significant pulmonary or hepatic complications after transplant. (© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|